HK1207861A1 - Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1 - Google Patents
Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1Info
- Publication number
- HK1207861A1 HK1207861A1 HK15108514.3A HK15108514A HK1207861A1 HK 1207861 A1 HK1207861 A1 HK 1207861A1 HK 15108514 A HK15108514 A HK 15108514A HK 1207861 A1 HK1207861 A1 HK 1207861A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- bub1
- cycloalkenopyrazoles
- cancer
- substituted
- treatment
- Prior art date
Links
- 101150076596 bub-1 gene Proteins 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12167690 | 2012-05-11 | ||
PCT/EP2013/059666 WO2013167698A1 (en) | 2012-05-11 | 2013-05-08 | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1207861A1 true HK1207861A1 (en) | 2016-02-12 |
Family
ID=48407563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15108514.3A HK1207861A1 (en) | 2012-05-11 | 2015-09-01 | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20150141372A1 (hu) |
EP (1) | EP2847180B1 (hu) |
JP (1) | JP2015520143A (hu) |
CN (1) | CN104411701B (hu) |
CA (1) | CA2872933A1 (hu) |
ES (1) | ES2620316T3 (hu) |
HK (1) | HK1207861A1 (hu) |
WO (1) | WO2013167698A1 (hu) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
CA2859779A1 (en) | 2011-12-21 | 2013-06-27 | Bayer Intellectual Property Gmbh | Substituted benzylpyrazoles |
US20160046610A1 (en) * | 2013-03-21 | 2016-02-18 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
JP2016514717A (ja) * | 2013-03-21 | 2016-05-23 | バイエル ファーマ アクチエンゲゼルシャフト | ジアミノヘテロアリール置換インダゾール |
CA2907594A1 (en) * | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted indazoles |
EP3010907A1 (en) | 2013-06-21 | 2016-04-27 | Bayer Pharma Aktiengesellschaft | Diaminoheteroaryl substituted pyrazoles |
EP3010901B1 (en) | 2013-06-21 | 2017-09-13 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
CA2916116A1 (en) | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
JP2016536311A (ja) | 2013-10-30 | 2016-11-24 | バイエル ファーマ アクチエンゲゼルシャフト | ヘテロアリール置換ピラゾール類 |
UY36175A (es) * | 2014-06-17 | 2016-01-29 | Bayer Pharma AG | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas |
CN107001331A (zh) | 2014-09-19 | 2017-08-01 | 拜耳制药股份公司 | 作为bub1抑制剂的苄基取代的吲唑 |
MY182181A (en) | 2015-01-28 | 2021-01-18 | Bayer Pharma AG | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
EP3310775B1 (en) * | 2015-06-17 | 2020-04-01 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
CN107921286A (zh) * | 2015-08-05 | 2018-04-17 | 拜耳制药股份公司 | 1h‑吡咯‑3‑胺类化合物 |
US20200216439A1 (en) * | 2015-12-16 | 2020-07-09 | Bayer Pharma Aktiengesellschaft | Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones |
WO2017148995A1 (en) | 2016-03-04 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity |
WO2017157992A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders |
WO2017157991A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases |
WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
WO2018158175A1 (en) | 2017-02-28 | 2018-09-07 | Bayer Pharma Aktiengesellschaft | Combination of bub1 inhibitors |
WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
US20230364070A1 (en) | 2020-09-23 | 2023-11-16 | Scorpion Therapeutics, Inc. | Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer |
WO2022072634A1 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Bicyclic compounds for use in the treatment cancer |
WO2022072645A2 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
IL301929A (en) | 2020-10-09 | 2023-06-01 | Scorpion Therapeutics Inc | Heterocyclic inhibitors of EGFR and/or 2HER for use in cancer treatment |
WO2022094271A1 (en) | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
WO2022098992A1 (en) | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
WO2022197913A1 (en) | 2021-03-18 | 2022-09-22 | Scorpion Therapeutics, Inc. | Bicyclic derivatives which can be used to treat cancer |
WO2023173083A1 (en) | 2022-03-11 | 2023-09-14 | Scorpion Therapeutics, Inc. | Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer |
EP4293019A1 (en) * | 2022-06-13 | 2023-12-20 | Netherlands Translational Research Center Holding B.V. | 4-substituted (1h-benzo[d]imidazol-2-yl)-1h-pyrazoles as bub1 inhibitors useful for treating cancers |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
GB9911053D0 (en) * | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
WO2001058857A1 (de) | 2000-02-10 | 2001-08-16 | Lonza Ag | Verfahren zur herstellung von alkoxymalonsäuredinitrilen |
EP1351691A4 (en) * | 2000-12-12 | 2005-06-22 | Cytovia Inc | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF |
US20050209252A1 (en) * | 2002-03-29 | 2005-09-22 | Che-Ming Teng | Cancer treatment |
FR2875230A1 (fr) * | 2004-09-13 | 2006-03-17 | Sanofi Aventis Sa | Derives de pyrazole condense, leur preparation et leur application en therapeutique |
US20090263398A1 (en) * | 2006-07-14 | 2009-10-22 | Astex Therapeutics Limited | Pharmaceutical combinations |
WO2011115804A1 (en) * | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
UA111754C2 (uk) * | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
EP2594270A3 (en) * | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
-
2013
- 2013-05-08 ES ES13721755.0T patent/ES2620316T3/es active Active
- 2013-05-08 EP EP13721755.0A patent/EP2847180B1/en not_active Not-in-force
- 2013-05-08 CA CA2872933A patent/CA2872933A1/en not_active Abandoned
- 2013-05-08 US US14/400,315 patent/US20150141372A1/en active Granted
- 2013-05-08 WO PCT/EP2013/059666 patent/WO2013167698A1/en active Application Filing
- 2013-05-08 JP JP2015510822A patent/JP2015520143A/ja not_active Ceased
- 2013-05-08 CN CN201380036066.XA patent/CN104411701B/zh not_active Expired - Fee Related
-
2015
- 2015-09-01 HK HK15108514.3A patent/HK1207861A1/xx unknown
-
2017
- 2017-03-08 US US15/453,679 patent/US20170275267A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2872933A1 (en) | 2013-11-14 |
EP2847180B1 (en) | 2017-01-04 |
CN104411701A (zh) | 2015-03-11 |
WO2013167698A1 (en) | 2013-11-14 |
ES2620316T3 (es) | 2017-06-28 |
US20150141372A1 (en) | 2015-05-21 |
EP2847180A1 (en) | 2015-03-18 |
US20170275267A1 (en) | 2017-09-28 |
JP2015520143A (ja) | 2015-07-16 |
CN104411701B (zh) | 2017-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1207861A1 (en) | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1 | |
HRP20171474T1 (hr) | Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka | |
PT3418281T (pt) | Pirazolo[1,5-a]pirimidinas úteis como inibidores da quinase atr para o tratamento de doenças de cancro | |
HK1206338A1 (en) | Pyrimidine compounds for the treatment of cancer | |
PL2818482T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu | |
EP2964028A4 (en) | Compounds for treatment of cancer | |
PT2824114T (pt) | Composição farmacêutica para o tratamento do cancro | |
IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
EP2925752A4 (en) | PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT | |
HK1185874A1 (zh) | 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺 | |
HK1219737A1 (zh) | 用於治療癌症的新化合物 | |
HK1223832A1 (zh) | 用於癌症治療的激酶抑制劑 | |
EP2897607A4 (en) | BETA-HYDROLASE INHIBITORS FOR THE TREATMENT OF CANCER | |
GB201214877D0 (en) | Compounds for treatments of tumors | |
PL2855475T3 (pl) | Alfa-karboliny do leczenia nowotworu | |
IL234796B (en) | Compounds for the treatment of diseases related to ischemia-reperfusion | |
HK1206633A1 (en) | Composition for treatment of warts | |
IL237229A0 (en) | Methods of treating cancer using lipoplatin | |
IL231448A0 (en) | Phosphatidylinositol 3-kinase inhibitors for cancer treatment | |
AU2012901199A0 (en) | Kinase inhibitors for the Treatment of Cancer | |
HK1200094A1 (en) | Use of immunomodulators for the treatment of cancer | |
AP2015008905A0 (en) | Novel compounds for the treatment of cancer |